Questions About the 2013 Implementation of IPAB
by Tom Norton With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have...
View ArticleSaving Greece's Healthcare System: A Harbinger for Europe?
A just-published report from the European taskforce trying to help Greece crawl out of its crisis makes clear just how significant a role health reform is supposed to play in restoring health to the...
View ArticleThe African Markets Pharma Can't Ignore
In its new study on pharma market growth in Africa, IMS Health highlights three ‘rising star’ countries from the continent’s sub-Saharan region. According to Africa: A Ripe Opportunity, Nigeria,...
View ArticleJ.P. Morgan: Suits Take San Francisco
The perennial fat got chewed during the first two days at J.P. Morgan’s annual healthcare conference – buy back stock or raise dividends? – and the usual suspects lurked, but newcomers like Walgreens...
View ArticleOncologists, in Detail
On average, cancer docs in the US would much rather deal with pharma sales reps in person as opposed to online, and drug companies are hiring more reps to support a slew of newly approved oncologic...
View ArticleUN Pact Scuttles Anti-Vaccine Provision
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the...
View ArticlePharma Pricing Top Target for Medicare Cutbacks
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support: require drug companies to give the federal government “a better...
View ArticleState Surprises as Obamacare Starts Up
by Tom Norton This past week or so, with Obamacare’s start up less than a year away, we have been treated to several entertaining vignettes as the nation’s governors begin to wrestle with the realities...
View ArticlePatients on the Picket Line
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access...
View ArticleClik here to view.
Getting it Done in Washington
During his fifth State of the Union address, President Obama struck many familiar chords – including a line about ending certain subsidies to pharmaceutical companies – and emphasized, repeatedly, the...
View ArticlePart D Politics: Medicare Drug Rebates or Price Controls?
Jill Wechsler Blog – PE Feb. 22, 2013 Part D Politics: Medicare drug rebates or price controls? While health care was barely mentioned in the recent State of the Union address, President Obama...
View ArticlePackaging: Regulators Call for Better Patient Information
By Jacob Presson, Research Analyst at Cutting Edge Information. Regulations concerning the contents of patient package inserts (known in the EU as “patient information leaflets” or PILs) have in the...
View ArticleReflections on Rare Disease Day
The rare disease advocacy community convened yesterday for its annual Rare Disease Day celebration, marking another year of advances in the fight against ailments once almost entirely ignored by big...
View ArticleePharma Summit: Turning Big Data into Better Content
Physicians and patients are more intimately engaged with their digital devices than ever before, but the content pharma delivers is either rigidly scientific or numbingly bland. Can stronger analytical...
View ArticleFollowing Industry, OPDP Hopes to Eliminate Silos in Ad Review
The Office of Prescription Drug Promotion (OPDP) is reorganizing its two primary advertising review divisions – professional and consumer – in an attempt to stay in line with the silo-breaking,...
View ArticleChanging the DNA of Pharma Patient Adherence Programs
by Grant Corbett Epigenetics is the study of changes in human gene expression, in particular from environmental factors. Pharma is also experiencing epigenetic change. Human genes are formed from...
View ArticleSequestration: How Big a Hit for FDA, Research and Pharma?
The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued...
View ArticleClik here to view.
Congress, FDA Should Consider Tech Solutions for Safer Compounding
By Niels Erik Hansen Niels Erik Hansen, president and CEO of Intelligent Hospital Systems Last fall’s deadly meningitis outbreak linked to contaminated steroid injections is a tragic reminder of the...
View ArticleAre US and Canadian Rx Policies Converging?
by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed...
View ArticleHealthcare Systems in Europe "Failing Patients"
By Reflector, Brussels correspondent. Any complacency that the world of healthcare might be feeling about advances in the ability to treat patients suffered a head-on assault in Dublin, Ireland, last...
View Article
